Cannabis research is not evenly spread. A few conditions have licensed medicines or randomised trials behind them. Others have small observational studies, surveys or laboratory work and little else.
The guides below show what was studied and what the results were. Links to cannabinoids and terpenes lead to the compounds named in that research.
Pain and neurological conditions
- Chronic pain (NICE context) — the evidence behind NICE guideline NG144
- Neuropathic pain — the Cochrane review and individual randomised trials
- Fibromyalgia — small trials and observational studies
- Migraine and headache disorders — one acute migraine trial and no prevention trials
- Arthritis and joint pain — negative CBD trials alongside cell and animal research
- Multiple sclerosis spasticity — nabiximols, its licence and NICE guidance
- Parkinson’s disease — four randomised trials and their safety findings
- Endometriosis — survey evidence, with no clinical trials yet
Mental health and neurodevelopmental conditions
- Anxiety disorders — CBD laboratory studies, THC dose effects and the missing disorder-level trials
- Post-traumatic stress disorder — endocannabinoid research and one small nabilone trial
- Depression — limited, mixed evidence and reports of symptoms worsening
- ADHD — one pilot trial with a non-significant primary result
- Autism — trials of CBD-rich extracts measuring co-occurring features
- Tourette’s syndrome — two randomised trials, including CANNA-TICS
Gastrointestinal, sleep and other conditions
- Inflammatory bowel disease — small Crohn’s and ulcerative colitis trials
- Sleep disorders — negative CBN trials and modest THC findings
- Treatment-resistant epilepsy — Epidyolex and the Dravet and Lennox-Gastaut trials
- Chemotherapy-induced nausea — nabilone trials and current antiemetic guidance
- Palliative care — limited trials covering appetite, pain and nausea
- ME/CFS — high patient interest and very little clinical research
Additional conditions
- HIV/AIDS — limited clinical research on symptom and medication side-effect management
- Schizophrenia risk — evidence on cannabis use, risk, and clinical guidance
- Addiction and substance use — cannabis and opioid, alcohol, and stimulant use disorders
- Cancer — symptom management research, not cancer treatment
- ALS/Motor neuron disease — early research on spasticity and symptom control
- Diabetes and metabolic health — observational data on glucose, insulin, and body weight
- Stroke — cannabis, cerebrovascular risk, and post-stroke recovery research
- Alzheimer’s and dementia — preclinical neuroprotection research; no clinical trials showing benefit
- Bipolar disorder — limited evidence with concerns about mood episode risk
- OCD — small exploratory studies and preclinical rationale
- Asthma — respiratory considerations and what limited research exists
Follow the compounds
The cannabinoid library covers THC, CBD, CBG, CBN, CBC, THCV, CBGA and THCA. The terpene library covers twenty-one compounds including myrcene, caryophyllene, limonene, pinene and linalool.
For UK access and prescription questions, use the patient guide. Driving, interactions and impairment are covered in safety, legal and driving.
Strain selection is cultivar-level context
Strain identities carry genetics, terpene profiles, and sensory notes that sit outside condition-level evidence. If you are asking "which strain?" for a particular condition, that is a cultivar question, not a clinical evidence question. See Strains.cc for cultivar discovery and review context.